Automate Your Wheel Strategy on NUVB
With Tiblio's Option Bot, you can configure your own wheel strategy including NUVB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NUVB
- Rev/Share 0.0324
- Book/Share 1.2388
- PB 1.8083
- Debt/Equity 0.0272
- CurrentRatio 9.0117
- ROIC -0.4614
- MktCap 759949120.0
- FreeCF/Share -0.3392
- PFCF -6.6171
- PE -1.2508
- Debt/Assets 0.0232
- DivYield 0
- ROE -1.4761
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NUVB | Citizens JMP | -- | Mkt Outperform | -- | $6 | April 23, 2025 |
News
Nuvation Bio Inc. (NUVB) Q1 2025 Earnings Call Transcript
Published: May 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Nuvation Bio Inc. (NYSE:NUVB ) Q1 2025 Earnings Call May 7, 2025 4:30 PM ET Company Participants J.R. DeVita - Investor Relations David Hung - Founder, President and Chief Executive Officer Colleen Sjogren - Chief Commercial Officer Philippe Sauvage - Chief Financial Officer Conference Call Participants Gregory Renza - RBC Capital Markets Kaveri Pohlman - Clear Street Soumit Roy - Jones Research Michael Yee - Jefferies Yaron Werber - TD Cowen Operator Good afternoon and welcome to the Nuvation Bio First Quarter 2025 Financial Results and Business Update Conference Call.
Read More
Nuvation Bio Inc. (NUVB) Reports Q1 Loss, Tops Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.16 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago.
Read More
Nuvation Bio: A Real Shot To Move The Needle In Lung Cancer Subtypes
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Positive
Nuvation Bio's taletrectinib shows strong efficacy in ROS1-positive NSCLC, with a 90.1% response rate, and FDA approval is likely by June 2025. Financially robust, Nuvation Bio has over three years of cash runway and additional liquidity options to support taletrectinib's launch and ongoing research. Despite strong data, competition from Bristol Myers Squibb's repotrectinib and other ROS1 players, and market hesitancy pose challenges for taletrectinib's market penetration.
Read More
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
Published: February 18, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 18, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nuvation Bio Inc. (NYSE: NUVB) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Read More
Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Positive
Nuvation Bio, listed via SPAC in 2021, and acquired AnHeart Therapeutics last year, gaining taletrectinib, a promising ROS1 inhibitor indicated for NSCLC. The FDA has accepted Nuvation's New Drug Application for the drug, assigning it priority review and a PDUFA date of June 23, 2025. Taletrectinib shows clearly superior clinical data compared to rivals, with a potential market opportunity of ~$3.8bn by its fourth year, despite current market skepticism.
Read More
About Nuvation Bio Inc. (NUVB)
- IPO Date 2020-08-26
- Website https://www.nuvationbio.com
- Industry Biotechnology
- CEO Dr. David T. Hung M.D.
- Employees 273